澳华内镜(688212.SH)2025年度归母净利润1146.19万元，减少45.45%

Core Viewpoint - The company reported a slight increase in revenue for the fiscal year 2025, but experienced a significant decline in net profit due to changes in sales structure and increased operational costs [1] Group 1: Financial Performance - The company achieved an operating revenue of 774 million yuan, representing a year-on-year growth of 3.20% [1] - The net profit attributable to the parent company was 11.46 million yuan, a decrease of 45.45% compared to the previous year [1] - The net loss attributable to the parent company, after excluding non-recurring gains and losses, was 7.11 million yuan [1] Group 2: Market and Product Developments - The company made significant progress in overseas market access and business expansion, resulting in rapid growth in overseas sales [1] - The successful launch of the new flagship model AQ400 contributed positively to revenue growth [1] Group 3: Cost Structure and Investment - There was a phase change in the product sales structure, leading to a decline in overall gross margin [1] - The company continued to invest heavily in marketing system construction, brand influence enhancement, product iteration, and new technology research and development, resulting in high sales, management, and R&D expenses [1]